For cancer patients, e-cigarettes not helpful for smoking cessation
the ONA take:
According to a new study published in the journal Cancer, patients with cancer who use e-cigarettes as a form of smoking cessation are equally or less likely to quit smoking compared with those who do not use e-cigarettes. Researchers from Memorial Sloan-Kettering Cancer Center in New York City, New York, sought to examine whether cancer patients using e-cigarettes affect smoking cessation due to the increased use of the device.
In the study, researchers followed 1,074 patients with cancer that smoke who were receiving care at a comprehensive cancer center and also part of a tobacco treatment program between 2012 and 2013. During that time, e-cigarette use rose from 10.6% to 38.5% of patients.
At follow-up, researchers found that the patients using e-cigarettes were equally as likely as non-users to still be smoking cigarettes. Furthermore, patients using e-cigarettes were found to be twice as likely to be regular smokers of cigarettes compared with non-users.
The American Cancer Society does not recommend for or against the the use of e-cigarettes for smoking cessation due to the lack of known and benefits and potential risks associated with long-term use.
Patients with cancer who use e-cigarettes are equally or less likely to quit smoking.
Despite the well-documented risks to health that are posed by smoking, previous research has shown that smoking habits can continue long after a cancer diagnosis has been made. The authors of the new study state that approximately two thirds of smokers diagnosed with cancer continue to do so after diagnosis.
This continuation is problematic, as smoking can cause new mutations among cancer survivors, resulting in secondary or further forms of primary cancer. Smoking can also reduce how effective cancer treatments are.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|